Introduction
Cell cycle progression is regulated by checkpoint controls, which function to protect the integrity of the genome. Such controls act to prevent cell cycle progression until after completion of prior events (Hartwell and Weinert, 1989) . The G 1 checkpoint permits repair prior to replication, whereas arrest at the G 2 checkpoint permits repair of the genome prior to its mitotic segregation. The p53 tumor suppressor gene, which is suppressed by mutation in approximately one-half of human tumors (Hollstein et al., 1991) , has been shown to be integral to both the G 1 (Kuerbitz et al., 1992) and G 2 (Bunz et al., 1998) DNA damage checkpoint machinery.
In addition to DNA damage checkpoints, cells undergo a transient arrest at the metaphase-anaphase transition point upon spindle damage (Rudner and Murray, 1996; Amon, 1999) . After a delay period, cells eventually escape from this block (a process termed 'mitotic slippage'), and exit mitosis without a proper segregation of sister chromatids and cytokinesis (Jordan et al., 1991 (Jordan et al., , 1996 Torres and Horwitz, 1998) . Therefore, spindle-damaged cells arrests at G 1 -like state with an intact nucleus containing 4N DNA, but without ever completing mitosis (Minn et al., 1996; Lanni and Jacks, 1998) . This is recently termed as tetraploid G 1 state.
Cells lacking wild-type p53 are still able to arrest transiently at mitosis, underscoring that the delay in mitosis is p53-independent (Minn et al., 1996; Lanni and Jacks, 1998) . However, the p53-deficient cells are not prevented from re-entering the cell cycle and can reduplicate their DNA unchecked, leading to polyploidy and subsequent genomic instability (Di Leonardo et al., 1997; Khan and Wahl, 1998; Lanni and Jacks, 1998) . In addition to microtubule inhibitors, dihydrocytochalasin B (DCB), which induces cleavage failure by depolymerizing actin filaments, also lead to tetraploid G 1 arrest (Andreassen et al., 2001) . Since DCB does not affect to spindle function and chromatid segregation, but only inhibits cytokinesis, it is likely that tetraploid G 1 checkpoint seems to be a general checkpoint control acts in G 1 to recognize tetraploid cells and induce their arrest, and thereby prevents the propagation of errors of late mitosis and the generation of aneuploidy.
We previously reported that loss of p53 sensitizes tumor cells to actin damage induced by treatment with actin-depolymerizing or knotting agents (Chae et al., 2005) . Upon actin damage, Bim expression was induced in tumor cells lacking functional p53, but not in cells with functional p53 (Chae et al., 2005) . In this study, we found the deregulation of Cdk2 in p53-deficient tumor cells caused abrogation of tetraploid G 1 checkpoint arrest and Bim-mediated apoptosis after actin damage.
Results

Actin inhibitors activate p53-signaling pathway
We previously reported that actin damage induces Bimmediated apoptosis in p53-deficient tumors (Chae et al., 2005) . In this study, we first examined whether actin inhibitors affect p53-signaling pathway. Western blot analysis showed that actin-depolymerizing agent, pectenotoxin-2 (PTX-2) increased the protein levels of p53 and p21 tumor suppressor proteins in HCT116 colon cancer cell lines (Figure 1a ). Other actin inhibitors such as cytochalasin D and psychosine, which cause depolymerization and knotting, respectively, of actin filaments also increased expression of p53 and p21 (Figure 1a ). PTX-2 also increased p53 and p21 in HepG2 cells that harbor wild-type p53, but not in Hep3B and H1299 lacking functional p53 (Figure 1b) .
We further examined alterations of cell cycle regulators upon PTX-2 treatment. Among cyclins and Cdks, cyclins A, B and Cdc2 were decreased, whereas cyclins D and E were increased by PTX-2 treatment in p53-positive HCT116 cells (Figure 1c) . However, the reduction of cyclins A, B and Cdc2 was not prominent in p53-and p21-knockout HCT116 cells, implying that p53 and p21 are required for decreases in protein levels of Cdc2, cyclins A and B (Figure 1c ). immunoprecipitation (IP)-kinase assay showed that while both Cdk2 and Cdc2 were not detected in HCT116 cells, both kinases remain unchanged in p53-and p21-knockout cells following PTX-2 treatment (Figure 1c) . Therefore, inactivation of Cdk2 and Cdc2 kinases in p53-positive cells should be due to p21-mediated inhibition, supporting our previous report that p21-mediated Cdk2 inhibition lead to Cdc2 inactivation (Yun et al., 2003; Chae et al., 2004) .
Absence of p53 causes polyploidy and multinucleation DNA content analysis revealed that parental HCT116 cells showed 4 or 8N DNA content, while the p53-and p21-knockout cells exhibited polyploidy with 16 and 32N DNA content after treatment with all three actin inhibitors ( Figure 2a ). In addition, the sub-G 1 population significantly increased in the p53-and p21-knockout cells, but not in their parental cells (Figure 2b ), supporting previous report that p53-deficient tumor cells have the enhanced sensitivity to actin-damaging drugs (Chae et al., 2005) . Because populations with 16 and 32N DNA content were not less increased as compared to reduction of cells with 4 and 8N DNA content, it is likely that polyploid cells move to sub-G 1 populations. Reduction of populations with 4 and 8N and increases in sub-G 1 populations were also observed in other p53-deficient tumor cell lines such as H1299 and Hep3B, but not in HepG2 that harbors functional p53 (Figure 2b ).
While staining with 4 0 ,6-diamidino-2-phenylindole (DAPI) showed that about 90% of parental HCT116 cells arrested with two nuclei, a majority of the p53-and p21-knockout cells became multinucleate, containing four or more nuclei after treatment with PTX-2 (Figures 3a and b). Since DNA replication uncoupled from mitosis causes polyploidy and multinucleation, we examined whether the p53-and p21-knockout cells treated with PTX-2 undergo DNA synthesis. 5-Bromo-2 0 -deoxy-uridine (BrdU) incorporation was significantly decreased after PTX-2 treatment in parental HCT116 cells, but not in the p53-and p21-knockout cells, implying that p53 and p21 are essential to prevent DNA replication in PTX-2-treated cells ( Figure 3c ). We also examined the rate of mitosis entry after PTX-2 treatment using two-dimensional flow cytometry for both DNA content and the mitotic marker mitotic protein monoclonal 2 (MPM-2), in which mitotic content was quantitated from two-dimensional dot plots of DNA content versus MPM-2 stain by flow cytometry. p53-and p21-knockout cells entered mitosis at similar rate even after PTX-2 treatment as compared to nontreated cells (Figure 3d ). These results suggest that p53 and p21 are required for preventing mitosis entry as well as DNA replication following PTX-2 treatment. Figure 1 Actin inhibitors activate the p53/p21 signaling pathway. (a) Expression of p53 and p21 following treatment with actin inhibitors. HCT116 cells were treated with pectenotoxin-2 (PTX-2) (100 ng ml À1 ), cytochalasin D (10 mM) or psychosine (50 mM) for the indicated periods and were then analysed for p53 and p21 proteins. (b) Tumor cells lines that randomly selected were treated with PTX-2 for 2 days and analysed for p53 and p21 proteins. (c) HCT116 and its p53-and p21-knockout derivatives were treated with PTX-2 (100 ng ml
À1
) and were analysed for cell cycle-regulatory proteins. Histone H1 kinase activity was measured by the precipitates formed with the anti-Cdk2 and anti-Cdc2 antibodies in cells after PTX-2 treatment at 100 ng ml À1 for the indicated periods. As shown is a representative of more than three independent experiments.
Inhibition of Bim-mediated apoptosis by Bcl-x L and Cdk inhibitors Since we previously reported that induction of Bim expression initiates apoptosis following actin inhibitor treatment, we examined the effects of Bcl-x L , which is a member of anti-apoptotic Bcl-2 family and antagonize Bax and Bak (Sedlak et al., 1995; Antignani and Youle, 2006) . Enforced expression of Bcl-x L increased viability of p53-knockout cells following PTX-2 treatment (Figure 4a ). However, flow cytometric analysis showed that Bcl-x L increased populations of polyploid cells in association with decrease in sub-G 1 populations (Figure 4b ), implying that Bcl-x L inhibits apoptosis of polyploid cells. In addition, Bcl-x L did not affect induction of Bim expression in p53-knockout cells upon treatment with PTX-2 (Figure 4c ).
To examine whether constitutive activation of Cdk2 in p53-or p21-knockout cells contribute to Bimmediated apoptosis, we treated cells with the Cdk2 inhibitors such as roscovitine and olomoucine as well as iso-olomoucine, an inactive analog of olomoucine, and examined their effects on apoptosis induction (Figure 5a ). The inhibitors suppressed not only accumulation of multinucleated cells, but also apoptotic cell deaths following PTX-2 treatment (Figure 5a ). Furthermore, treatment with roscovitine and olomoucine inhibited both Cdk2 and Cdc2 kinases and induction of Bim expression following PTX-2 treatment (Figure 5b ). In addition, the protein levels of Bcl-2 and Mcl-1 were not changed by PTX-2 treatment (Figure 5b) .
To further analyse a role of deregulated Cdk2 kinase, we expressed a dominant negative mutant form of Cdk2, Cdk2dn in p53-knockout cells (Figure 6 ). Expression of Cdk2dn, like Cdk2 inhibitors (Figure 5 ), inhibited cell death and suppressed accumulation of multinucleated cells following PTX-2 treatment (Figure 6a ). Protein analysis showed that Cdk2dn inhibited Bim expression, Bax activation, a release of cytochrome c and Smac/ Diablo into the cytosol and activation of caspase-9 and caspase-3 (Figure 6b ). Therefore, these results suggest that deregulation of Cdk2 causes Bim-mediated apoptosis in p53-deficient tumor cells following actin damage (Figure 7 ).
Discussion
The changes in PTX-2-treated p53-positive cells closely resemble those in normal cells treated with spindle inhibitors, which enter into tetraploid G 1 state (Lanni and Jacks, 1998) . Cyclins D and E were increased, but cyclins A and B were decreased following PTX-2 treatment (Figure 2a) , implying that those cells arrested at G 1 checkpoint. However, while normal human diploid fibroblast cells arrested at G 1 with 4N DNA content, majority of HCT116 and HepG2 contained 4 and 8N DNA (Figure 2) . Thus, those tumor cells, À/À and p21 À/À , were treated with PTX-2 at 100 ng ml À1 for the indicated periods and were then subjected to the BrdU incorporation assay as described in the Materials and methods. The percentage of BrdU-positive cells is shown as the mean ± s.e.m., n ¼ 3.
(d) Flow cytometric analysis of asynchronous HCT116 and HCT116 p53
À/À cultures either untreated or treated with 100 ng ml À1 PTX-2 for 2 days. Cells were labeled with the mitotic protein monoclonal 2 (MPM-2) antibody and propidium iodide (PI). MPM-2-positive mitotic cells were identified by flow cytometry, as described in the Materials and methods. A set of data representative of three independent experiments is shown. Percentages of MPM-2-positive cells were presented. although they harbor wild-type p53, may have other genetic defects involved in tetraploid G 1 arrest and genome instability.
However, unlike tetraploid G 1 arrest induced by spindle inhibitors, p53-and p21-knockout cells treated with actin inhibitors became multinucleate (Figure 3) . Since those cells maintained active Cdc2 and entered mitosis even after actin damage, multinucleation seems due to mitosis entry without cytokinesis. Thus, a p53/ p21-dependent backup mechanism is critical not only to À/À cells were treated with roscovitine (15 mM), olomoucine (30 mM), iso-olomoucine (30 mM) or the vehicle control with or without PTX-2 (100 ng ml
À1
) for 36 h. Whole cell (WCE) and mitochondrial (Mito) fractions were prepared. Figure 6 Cdk2dn suppressed Bim-mediated apoptosis. (a) Suppression of PTX-2-induced cell death and multinucleation by expression of Cdk2dn. p53-Knockout cells were infected with a recombinant adenovirus encoding Cdk2dn (Ad-Cdk2dn) or its control virus (Ad-DE1). One day after virus infection, the cells were treated with PTX-2 (100 ng ml À1 ) for 3 days. Then the viability and numbers of nucleus was determined. The percentage of dead cells (left panel) or multinucleate (right panel) is shown as the mean±s.e.m., n ¼ 3. (b) Cdk2dn inhibited Bim expression following PTX-2 treatment. Total, cytosol and mitochondrial fractions were prepared from lysates of p53-deficient cells treated as in (a) and were analysed for Bcl-2 family proteins, active caspase-3 (17 of 19 kDa), active caspase-9 (37 kDa), XIAP, Smac and cytochrome c. The representative data from more than three independent experiments are shown. sustain tetraploid G 1 arrest, but also inhibit mitosis entry following actin damage.
Cdk2dn and chemical inhibitors such as roscovitine and olomoucine suppressed accumulation of multinucleated cells by inhibiting both Cdk2 and Cdc2 kinases (Figures 5 and 6 ). Cdk2 inhibition in p53-knockout cells also caused inhibition of Bim-mediated apoptosis (Figures 5 and 6 ). However, it remains unclear whether Bim expression is affected directly by Cdk2 or merely a result of uncoupling between mitosis and DNA replication. It has been shown that FOXO1/3 can activate transcription of Bim (Stahl et al., 2002; Gilley et al., 2003; Barreyro et al., 2007) . However, actin damage did not increase phosphorylation and expression of FOXO1/3 after PTX-2 treatment (data not shown). Recent study reported that CHOP-C/EBPa can activate transcription of FOXO in a response to Endoplasmic reticulum stress (Puthalakath et al., 2007) , implying that multiple transcription factors can activate FOXO transcription in a response to environmental signals. Thus, it remains to be elucidated which mediates Bim expression in a response to actin damage.
Cells with overexpression of Bcl-x L have an increased rate of spontaneous tetraploidization (Minn et al., 1996; Castedo et al., 2006) , suggesting that apoptosis may play an important role in eliminating cells that fail to complete mitosis properly. We showed that Bcl-x L suppressed the apoptosis of p53-deficient cells by PTX-2. Instead of apoptotic death, p53-deficient cells with Bcl-x L became polyploidy (Figure 5b) . Therefore, these results support that Bcl-x L increases aneuploidy and genomic instability by preventing both p53-dependent and -independent apoptosis.
Materials and methods
Cell culture and transfection HCT116, a human colorectal cancer cell line, and its p53-and p21-knockout derivatives (denoted p53 À/À and p21
, respectively) were kindly provided by Dr Bert Vogelstein (John Hopkins Oncology Center, Baltimore, MD, USA). DNA transfections were performed using the CaPO 4 coprecipitation procedure (Graham and van der Eb, 1973) . HCT116 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Life Technologies Inc., Grand Island, NY, USA) and penicillin-streptomycin (50 U ml À1 ). To select stable cell lines expressing Bcl-x L , we transfected p53-knockout cells with pPuro-Bcl-x L . A recombinant adenovirus encoding Cdk2dn was constructed as previously described (Chae et al., 2004) .
Cell cycle analysis
For each DNA content analysis, 1 Â 10 6 cells were harvested by trypsinization and fixed by rapid submersion in 1 ml cold 70% ethanol. After fixation at À20 1C for at least 1 h, cells were pelleted and subsequently resuspended in 1 ml staining solution (50 mg ml À1 propidium iodide, 50 mg ml À1 RNase, 0.1% Triton X-100 in citrate buffer, pH 7.8) and analysed with Coulter EPICS XL (Coulter Electronics, Hialeah, FL, USA). For the determination of mitotic cells, labeling with MPM-2 antibody (Upstate Biotechnology, Charlottesville, VA, USA) was used: Cells were harvested at specific time points, and fixed with ice-cold 90% methanol. After washing with phosphatebuffered saline (PBS), the fixed cells were labeled with MPM-2 antibody (final concentration: 10 mg MPM-2 per ml) for 3 h at room temperature. The labeled cells were washed with PBS, incubated first with a fluorescein isothiocyanate-conjugated donkey anti-mouse immunoglobulin G secondary antibody and then with 50 mg ml À1 propidium iodide as described above. The cells staining positive for MPM-2 (circled) show increased fluorescence. The presented data are representative of more than three experiments.
Nuclear staining and the BrdU incorporation assay To assess nuclear morphology, we seeded HCT116, p53 À/À and p21 À/À cells on cover glasses, and after allowing them to grow for 36 h, treated them with PTX-2 (10 ng ml À1 ) for 3 days and finally fixed them in Cannoid fixative (methanol/acetic acid (3:1)). After staining the nuclei with DAPI (0.2 mg ml À1 , Sigma, St Louis, MO, USA), the distribution of cells with 1, 2 and X4 nuclei was determined for each group by observation of at least 600 cells. Proliferation assay was performed using a 5-Bromo-2 0 -deoxy-uridine Labeling and Detection Kit II (Roche, Mannheim, Germany). HCT116, p53-and p21-knockout cells were seeded on cover glasses, grown for 36 h before PTX-2 treatment (100 ng ml À1 ). After 1, 2 and 3 days, cells were labeled for 1 h with 10 mM BrdU and BrdUincorporated cells were detected with the manufacturer's instructions.
Western blot analyses
Protein (20 mg) was subjected to SDS-polyacrylamide gel electrophoresis and transferred to PolyScreen membranes (NEN, Boston, MA, USA). The membranes were subsequently blocked with 5% nonfat dry milk in Tris-buffered saline Tween-20 (Jung et al., 2001 ) and probed with antibodies. Figure 7 Schematic presentation of Bim-mediated apoptosis in p53-deficient tumor cells. Actin inhibitors that block cytokinesis activate p53-signaling pathway and hence arrests the cell cycle at G 1 checkpoint. However, tumor cells lacking p53 fail to inhibit DNA replication and mitosis entry by keeping both Cdk2 and Cdc2 kinases active, and hence become multinucleate and polyploidy.
The following antibodies were used in this study: antibodies against cleaved caspase-9 and cleaved caspase-3 (Cell Signaling Technology, Beverly, MA, USA); p21 (Oncogene, Boston, MA, USA); cyclins A, B, D, E, Cdk2, Cdk4, actin, Bax, p53 and HSP60 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Primary antibodies were detected with a horseradish peroxidase-conjugated goat anti-mouse, goat anti-rabbit or donkey anti-goat secondary antibody with enhanced chemiluminescence detection (Amersham, Buckinghamshire, UK).
In vitro kinase assay The specific activities of Cdk-cyclin complexes were determined by 32 P incorporation into substrates. For IP-kinase assay, cells were washed with cold PBS and lysed in RIPA buffer (50 mM Tris-HCl, pH 7.5, 5 mM NaCl, 1 mM EGTA, 1% Triton X-100, 50 mM NaF, 10 mM Na 3 VO 4 , 1mg ml À1 aprotinin, 1 mg ml À1 leupeptin, 1 mg ml À1 pepstatin A, 0.1 mM PMSF, 1 mM DTT). Extracts (200 mg total protein) were incubated for 12 h at 4 1C with 2 mg of the anti-Cdk2 (SC-163), anti-Cdc2 (SC-54, Santa Cruz Biotechnology) antibody. The immunoprecipitates were immobilized on protein A-agarose beads (Roche, IN, USA) by incubation for 4 h at 4 1C. The beads were washed twice with 1 ml RIPA buffer and twice more with kinase buffer (50 mM Tris-HCl, pH 7.4, 10 mM MgCl 2 , 1mM DTT). After the final wash, the immune complexes were suspended in 50 ml of the corresponding kinase buffer containing 20 mM ATP, 5 mCi [g-32 P]ATP and 2 mg histone H1 (Boehringer Mannheim). The reactions were allowed to proceed for 30 min at 30 1C. Phosphorylated proteins were separated on a 12% SDS-PAGE and visualized by autoradiography.
